Notable Mover: Does Organovo Holdings Inc Have Any Gas After Today’s Big Increase?

Notable Mover: Does Organovo Holdings Inc Have Any Gas After Today's Big Increase?

The stock of Organovo Holdings Inc (NASDAQ:ONVO) is a huge mover today! About 1.24 million shares traded hands or 70.60% up from the average. Organovo Holdings Inc (NASDAQ:ONVO) has risen 68.75% since March 2, 2016 and is uptrending. It has outperformed by 60.49% the S&P500.
The move comes after 5 months positive chart setup for the $366.70M company. It was reported on Oct, 5 by Barchart.com. We have $9.82 PT which if reached, will make NASDAQ:ONVO worth $535.38 million more.

Analysts await Organovo Holdings Inc (NASDAQ:ONVO) to report earnings on November, 14. They expect $-0.11 earnings per share, up 8.33% or $0.01 from last year’s $-0.12 per share. After $-0.09 actual earnings per share reported by Organovo Holdings Inc for the previous quarter, Wall Street now forecasts 22.22% negative EPS growth.

According to Zacks Investment Research, “Organovo Holdings, Inc. is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. Its NovoGen 3D printing technology is a platform that works across various tissue and cell types. Organovo Holdings, Inc. is based in San Diego, California.”

Insitutional Activity: The institutional sentiment decreased to 1 in Q2 2016. Its down 0.52, from 1.52 in 2016Q1. The ratio turned negative, as 3 funds sold all Organovo Holdings Inc shares owned while 35 reduced positions. 11 funds bought stakes while 27 increased positions. They now own 17.18 million shares or 1.14% less from 17.37 million shares in 2016Q1.
Royal State Bank Of Canada has invested 0% of its portfolio in Organovo Holdings Inc (NASDAQ:ONVO). Ameriprise Financial Inc has 19,902 shares for 0% of their US portfolio. National Bank Of America De last reported 0% of its portfolio in the stock. Dumont Blake Investment Limited Liability owns 12,800 shares or 0.01% of their US portfolio. Vanguard Group owns 3.38M shares or 0% of their US portfolio. Moreover, Fil Ltd has 0% invested in Organovo Holdings Inc (NASDAQ:ONVO) for 373,571 shares. Tradewinds Mngmt Limited Liability has 30 shares for 0% of their US portfolio. Barclays Public Limited Liability Corp holds 215 shares or 0% of its portfolio. Finemark Commercial Bank Tru accumulated 0% or 2,000 shares. Blackrock Mgmt Ltd Llc reported 337,533 shares or 0% of all its holdings. Finance Architects Incorporated holds 450 shares or 0% of its portfolio. Valley Natl Advisers Inc holds 4,150 shares or 0.01% of its portfolio. House Ltd Llc has 0.01% invested in the company for 10,625 shares. The Connecticut-based Paloma Prtn Mgmt Com has invested 0% in Organovo Holdings Inc (NASDAQ:ONVO). West Oak Capital Lc last reported 2,000 shares in the company.

Insider Transactions: Since August 5, 2016, the stock had 0 insider purchases, and 1 sale for $91,000 net activity. $91,000 worth of shares were sold by David Eric on Friday, August 5.

More notable recent Organovo Holdings Inc (NASDAQ:ONVO) news were published by: Fool.com which released: “Organovo Holdings, Inc. in 3 Charts” on September 22, 2016, also Fool.com with their article: “How Risky Is Organovo Holdings, Inc.?” published on September 12, 2016, Fool.com published: “Why Organovo Holdings Inc. Is Up 27% This Year” on June 30, 2016. More interesting news about Organovo Holdings Inc (NASDAQ:ONVO) were released by: Fool.com and their article: “The Possible Reason Behind Organovo Holdings, Inc.’s Big Climb in April” published on May 05, 2016 as well as Fool.com‘s news article titled: “5 Things Organovo Holdings, Inc. Management Wants You to Know” with publication date: June 13, 2016.

ONVO Company Profile

Organovo Holdings, Inc., incorporated on January 27, 2012, is an early commercial-stage firm focused on developing and commercializing functional human tissues that can be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs. The Firm focuses on the generation of three-dimensional (3D) human tissues, by utilizing its platform technology to create human tissue constructs in 3D that mimic native human tissue composition, architecture and function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment